



Recombinant Human Claudin 18.2 VLP (DAG-WT1229)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Species	Human
Purity	> 95% as determined by HPLC
Conjugate	N/A
Applications	ELISA, SPR
Molecular Weight	29 kDa
Reconstitution	Reconstituting to a concentration more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water.
Format	Lyophilized
Size	100 µg, 500 µg
Buffer	Lyophilized from 0.22um filtered solution in PBS, pH 7.4. Normally 8% trehalose is added as protectant before lyophilization
Preservative	None
Storage	Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week

BACKGROUND

Introduction	Claudin-18.2 (CLDN18.2) has become a promising target for the treatment of patients with digestive malignancies, such as gastric cancer (GC), gastroesophageal junction (GEJ) cancer, esophageal cancer, and pancreatic cancer, because of its limited expression in healthy tissues
---------------------	--

and abnormal overexpression in a range of malignancies. Multiple clinical trials of CLDN18.2-targeted therapies, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and chimeric antigen receptor (CAR) T-cell therapies, are ongoing, with some showing promising early results.

Keywords	Claudin-18.2; CLDN18.2
-----------------	------------------------

GENE INFORMATION

UniProt ID	P56856-2
-------------------	----------
